Address
3800 Bridge Parkway
Redwood City, CA 94065
United States of America (the)
Phone
650 453 0000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
134
First IPO Date
December 04, 2020
| Name | Title | Pay | Year Born |
| Omid C. Farokhzad | Founder, Chief Executive Officer, & Chair of the Board of Directors | 1.21M | 1969 |
| David R. Horn | President,Treasurer & Chief Financial Officer | 744,805 | 1968 |
| Asim Siddiqui | Senior Vice President of Research & Tech Development | 0 | N/A |
| Anthony Bazarko | Chief Commercial Officer | 0 | N/A |
| Martin Goldberg | Senior Vice President of Product Development | 0 | N/A |
| Marissa Dixon | Chief People Officer | 0 | N/A |
| Serafim Batzoglou | Chief Data Officer | 0 | N/A |
| Kenny Ross | Chief Operations & Product Officer | 0 | N/A |
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.